FDA Initiative Encourages Use Of Imaging Technologies To Identify Biomarkers
This article was originally published in The Pink Sheet Daily
Executive Summary
An FDA working group will develop guidance on the use of imaging to speed drug development. Locating the biomarkers will require coordination between manufacturers and the imaging industry.
You may also be interested in...
FDA's Woodcock Keynotes Meeting On Imaging In Drug Development
The agency's Critical Path initiative targets identification of surrogate endpoints using imaging technologies. DIA and BIO are cosponsoring the May 5-6 conference with FDA.
FDA's Woodcock Keynotes Meeting On Imaging In Drug Development
The agency's Critical Path initiative targets identification of surrogate endpoints using imaging technologies. DIA and BIO are cosponsoring the May 5-6 conference with FDA.
PPD Sees Biomarkers As Key To Drug Development
The company is seeking to accelerate its acquisition of SurroMed's biomarker discovery services business, with the goal of closing a deal in the first quarter of 2005. FDA has placed biomarker development "near the top" of its "Critical Path" initiative, PPD CEO Eshelman notes.